Enhancing Access: Cross-Sector Collaboration in Healthcare

By Staff Writer

November 20, 2023

The Medicine Accessibility Challenge

High-income countries are increasingly struggling to afford medicines. New and established drugs are often too expensive and scarce. Gene and cell therapies, cancer pharmaceuticals, and orphan drugs are expensive and burden individuals and health systems.

Broken Pharma Systems

Pharmaceutical system fragmentation, especially in Europe, limits equal medicine availability. The outpatient and hospital sectors frequently have separate public bodies for medicine reimbursement and procurement. This distinction can cause differences in inpatient and outpatient medicine, which can have serious cost consequences, especially when hospitals start expensive therapy. The goal of a recent study was to determine whether cross-sectorial pharmaceutical policies improve medicine access in Europe.

Policymakers and Stakeholders

Policymakers and stakeholders are crucial to pharmaceutical reimbursement and procurement cross-sectorial collaboration. The roles include starting and assessing the collaboration. Policymakers can enable cross-sector collaboration with legal and regulatory frameworks. They can also start change and harmonise policy across industries. These policies can be developed and implemented using the skills and understanding of stakeholders. They can also promote collaboration benefits to stakeholders and the public. To be effective, these jobs require a productive atmosphere with trust, transparency, and stakeholder understanding.

Limitations and Future Plans for Cross-Sector Collaboration in Healthcare

The review focused on Europe, thus its findings may not apply to other regions. The evaluation did not examine cross-sector collaboration barriers, which would affect policy creation and implementation. Similar research in other regions and investigations of cross-sector collaboration barriers should solve these limitations. Longitudinal research are needed to assess how these agreements affect medicine access. This would strengthen evidence that cross-sector coordination improves access to inexpensive medicines.

Reference url

Recent Posts

cost-effective CML treatment
      

Cost-Effective CML Treatment in South Africa

💡 *Are we getting the most value from our cancer treatments? *
A new study reveals that imatinib is the most cost-effective treatment option for chronic myeloid leukemia (CML) in South Africa, outperforming nilotinib and dasatinib both in costs and quality-adjusted life years (QALYs). This analysis emphasises critical implications for the South African healthcare system, emphasising the need for price negotiations to enhance treatment access.

Explore the findings and their impact on healthcare policy and resource allocation.

#SyenzaNews #HealthEconomics #CostEffectiveness #HealthcarePolicy

endometrial cancer mortality
      

Trends in Endometrial Cancer Mortality

💭 Are we doing enough to address ethnic disparities in endometrial cancer mortality?
A recent study highlights alarming trends in endometrial cancer mortality rates in South Africa, where rates have nearly doubled from 1999 to 2018, with significant variations among different ethnic groups. Understanding these disparities is crucial for developing targeted public health strategies to improve outcomes.

Look into the full article to explore the key insights and implications for healthcare policy and intervention strategies.

#SyenzaNews #globalhealth #healthcarepolicy

HIV cancer care integration
       

HIV Cancer Care Integration in Sub-Saharan Africa

🌍 How can integrating HIV care transform cancer treatment in Africa?

Healthcare providers in Malawi, South Africa, Uganda, and Zimbabwe are optimistic about merging HIV support with cancer treatment, despite facing challenges like workspace constraints and financial pressures. This integration is key for enhancing patient outcomes and efficiency in care delivery.

Look into the insights and barriers identified in this crucial discussion.

#SyenzaNews #ClinicalTrials #GlobalHealth #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.